4-(piperidin-1-yl)benzene-1,2-diamine | 155198-10-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(piperidin-1-yl)benzene-1,2-diamine
• 英文别名: 2-amino-4-(piperidin-1'-yl)aniline；4-piperidin-1-ylbenzene-1,2-diamine
• CAS: 155198-10-0
• 化学式: C₁₁H₁₇N₃
• 分子量: 191.276
• InChiKey: AEINPSBURKLEEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  55.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(piperidin-1-yl)benzene-1,2-diamine 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 2-methylthio-5-piperidinobenzimidazole
  参考文献：
  名称：

  Iddon, Brian, Bulletin des Societes Chimiques Belges, 1990, vol. 99, # 9, p. 673 - 701

  摘要：

  DOI：
• 作为产物：
  描述：

  2-nitro-5-(1-piperidinyl)aniline 在 palladium on activated charcoal 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 4-(piperidin-1-yl)benzene-1,2-diamine
  参考文献：
  名称：

  Quantitative structure–activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents

  摘要：

  Several 5-substituted terbenzimidazoles were synthesized and evaluated as mammalian topoisomerase I poisons and for cytotoxicity against a human lymphoblastoma cell line, RPMI-8402. No correlation was observed between topoisomerase I poisoning activity and the Hansch pi value or the sigma(meta) and sigma(para) values associated with each substituent. These data suggest that electronic effects and relative lipophilicity of substituents at the 5-position of these terbenzimidazoles do not have a significant effect upon intrinsic topoisomerase I poisoning activity. There was, however, a good correlation between the relative pi values for the various subtituents evaluated and cytotoxic activity. Experimentally determined log P values did not correlate well with either cytotoxicity or pi values. Capacity factors (log k') as determined by high pressure liquid chromatography did correlate well with the it values of varied substituents and cytotoxicity. These data indicate that the relative lipophilic activity of substituents at the 5-position of these terbenzimidazoles can strongly influence relative cytotoxic activity. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(97)10021-9

文献信息

• Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy
  作者：Bo Kong、Zhaohong Zhu、Hongmei Li、Qianqian Hong、Cong Wang、Yu Ma、Wan Zheng、Fei Jiang、Zhimin Zhang、Ting Ran、Yuanyuan Bian、Na Yang、Tao Lu、Jiapeng Zhu、Weifang Tang、Yadong Chen

  DOI：10.1016/j.ejmech.2021.113953

  日期：2022.1

  modifications led to the identification of compound 35f as the most active inhibitor of BET BRD4 with selectivity against BET family proteins. Further biological studies revealed that compound 35f can arrest the cell cycle in G0/G1 phase and induce apoptosis via decreasing the expression of c-Myc and other proteins related to cell cycle and apoptosis. More importantly, compound 35f showed favorable pharmacokinetic

  作为表观遗传阅读器，溴结构域和末端外结构域 (BET) 家族蛋白与组蛋白中的乙酰化赖氨酸残基结合并募集蛋白质复合物以促进转录起始和延伸。通过小分子抑制剂抑制 BET 溴结构域已成为一种有前途的癌症治疗策略。在这里，我们描述了我们为发现一系列新的 1-(5-(1 H -benzo[ d ]imidazole-2-yl)-2,4-dimethyl-1 H -pyrrol-3-yl)ethan 所做的努力-1-one 衍生物作为 BET 抑制剂。密集的结构修饰导致化合物35f被鉴定为对 BET 家族蛋白具有选择性的最活跃的 BET BRD4 抑制剂。进一步的生物学研究表明，化合物35f通过降低c-Myc等细胞周期和细胞凋亡相关蛋白的表达，使细胞周期停滞在G 0 /G 1期，诱导细胞凋亡。更重要的是，化合物35f在 MV4-11 小鼠异种移植模型中显示出良好的药代动力学特性和抗肿瘤功效，具有可接受的耐受性。这些结果表明，BET
• 2H-benzimidazoles (isobenzimidazoles). Part 10. Synthesis of polysubstituted o-phenylenediamines and their conversion into heterocycles, particularly 2-substituted benzimidazoles with known or potential anthelminthic activity
  作者：Justine C. Hazelton、Brian Iddon、Hans Suschitzky、Ley H. Woolley

  DOI：10.1016/0040-4020(95)00642-l

  日期：1995.9

  Polysubstiluted o-phenylenediamines were syathesised in moderate to high yield by reductive cleavage of the corresponding 2H-benzimidazole-2-spirocyclohexane with sodium dithionite in aqueous ethanol and converted into methyl benzimidazole-2-carbamates and 2-methylthio-and 2-trifluoromethylbenzimidazoles with known or potential anthelminthic activity. 5-(Pyrimidin-2-ylthio)-benzimidazole and 1 l-(

  通过用连二亚硫酸钠在乙醇水溶液中还原裂解相应的2 H-苯并咪唑-2-螺环己烷，可以中等至高收率合成多取代的邻苯二胺，然后将其转化为甲基苯并咪唑-2-氨基甲酸酯和2-甲硫基和2-三氟甲基苯并咪唑已知或潜在的驱虫活性。还合成了5-（嘧啶-2-基硫基）-苯并咪唑和1l-（吡啶-2-基硫基）二烯并[ a，c ]吩嗪。将2，3-二氨基喹喔啉与环己酮缩合制备的1，3-二氢-2 H -4，9-二氮杂[2，3- d ]咪唑的尝试氧化为标题体系的类似物失败。
• Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1<i>H</i>-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation
  作者：Wei Yan、Xinyi Wang、Yang Dai、Bin Zhao、Xinying Yang、Jun Fan、Yinglei Gao、Fanwang Meng、Yuming Wang、Cheng Luo、Jing Ai、Meiyu Geng、Wenhu Duan

  DOI：10.1021/acs.jmedchem.6b00056

  日期：2016.7.28

  Fibroblast growth factor receptor (FGFR) represents an attractive oncology target for cancer therapy in view of its critical role in promoting cancer formation and progression, as well as causing resistance to approved therapies. In this article, we describe the identification of the potent pan-FGFR inhibitor (R)-21c (FGFR1–4 IC50 values of 0.9, 2.0, 2.0, and 6.1 nM, respectively). Compound (R)-21c

  鉴于成纤维细胞生长因子受体（FGFR）在促进癌症形成和进展以及引起对批准疗法的抗性中起关键作用，因此它是癌症治疗的有吸引力的肿瘤学靶标。在本文中，我们描述了有效的泛FGFR抑制剂（的识别- [R ）- 21C（FGFR1-4 IC 50个的值0.9，2.0，2.0，和6.1 nM的，分别地）。化合物（R）-21c对一组FGFR扩增的细胞系表现出优异的体外抑制活性。Western印迹分析表明（[R ）- 21C抑制FGF / FGFR和下游信号传导途径在纳摩尔浓度。而且， （[R ）- 21C提供在NCI-H1581肿瘤生长（96.9％TGI）几乎完全抑制（FGFR1扩增）在通过口服给药，剂量为10毫克/公斤/ QD异种移植小鼠模型。
• Benzimidazole derivatives as antiulcer agents, process for their
  申请人：Dr. Reddy's Research Foundation

  公开号：US06051570A1

  公开（公告）日：2000-04-18

  This invention particularly relates to novel pyridylmethylsulfinyl benzimidazole represented by the general formula (I), its tautomers, its derivatives, its analogs, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates and pharmaceutical compositions containing them and the use thereof. ##STR1## The present invention also relates to a process for the preparation of the above said novel pyridylmethylsulfinyl benzimidazoles and pharmaceutical compositions containing them.

  本发明特别涉及一种由通式（I）表示的新型吡啶甲基亚磺酰基苯并咪唑，其互变异构体、衍生物、类似物、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的制药组合物以及它们的使用。 ##STR1## 本发明还涉及上述新型吡啶甲基亚磺酰基苯并咪唑和含有它们的制药组合物的制备方法。
• JAK-2 Modulators and Methods of Use
  申请人：Galan Adam Antoni

  公开号：US20100136136A1

  公开（公告）日：2010-06-03

  This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.

  本发明涉及蛋白酪氨酸激酶及其抑制剂领域。具体而言，本发明涉及JAK-2的抑制剂，以及用于抑制JAK-2的化合物的制药组合物，包括通过将含有本发明化合物的化合物或制药组合物与需要抑制JAK-2的细胞接触来抑制JAK-2的细胞方法。本发明还包括治疗涉及JAK-2的疾病或病状的方法，包括向患者施用包含本发明化合物的制药组合物。